Entry into the development, manufacture and sale of CAR-T cell therapies
First written in FY2018. 16 of 25 entries say "Advanced", first in FY2019-Q1. Latest entry: 2026-10-30.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Nagoya University has begun a physician-initiated Phase I/II clinical trial of the company's autologous CAR-T cell product for acute lymphoblastic leukemia (ALL), and the trial is currently under way, with completion expected in the fiscal year ending March 2027.」
For the autologous CAR-T cell product, a physician-initiated Phase I/II clinical trial of the company's manufactured product for ALL is under way, with completion expected in the fiscal year ending March 2027. - FY2026-H1AdvancedAnnual report
「Nagoya University has begun a physician-initiated clinical trial of the company's autologous CAR-T cell product for acute lymphoblastic leukemia, and preparations for the trial are progressing.」
For the autologous CAR-T cell product, a physician-initiated clinical trial for acute lymphoblastic leukemia using the company's manufactured product was initiated. - FY2025AdvancedAnnual report
「Nagoya University has begun physician-initiated clinical trials of the autologous CAR-T cell product manufactured by the company for malignant lymphoma and acute lymphoblastic leukemia.」
For the CAR-T cell product, a physician-initiated clinical trial for acute lymphoblastic leukemia was launched in addition to the existing trial for malignant lymphoma, advancing to the stage at which the company manufactures the product for the trials. - FY2025-H1AdvancedAnnual report
「Nagoya University has begun a physician-initiated clinical trial in Japan of the autologous CAR-T cell product for malignant lymphoma, and the company is manufacturing the CAR-T cells for use in the trial.」
For the CAR-T cell product, Nagoya University began a physician-initiated clinical trial in Japan for malignant lymphoma, advancing to the stage at which the company is responsible for manufacturing the CAR-T cells for the trial. - FY2024RestatedAnnual report
「In addition, Nagoya University plans to initiate in Japan a physician-initiated clinical trial of CAR-T cell therapy for malignant lymphoma, for which efficacy was confirmed in a clinical study at Chulalongkorn University in Thailand. The company is preparing to manufacture the CAR-T cells for use in the physician-initiated clinical trial in Japan.」
For the CAR-T cell product, the company continues to prepare to manufacture the product for Nagoya University's physician-initiated clinical trial in Japan, following reports of efficacy in the overseas clinical study. - FY2024-Q1AdvancedAnnual report
「In addition, in March 2023, it was reported that a clinical study at Chulalongkorn University in Thailand supported by Nagoya University had produced therapeutic effects in 5 patients with malignant lymphoma. It was also reported that Nagoya University plans to initiate a physician-initiated clinical trial in Japan using CAR-T cells to treat malignant lymphoma, and that the company plans to manufacture the CAR-T cells for use in the physician-initiated clinical trial in Japan.」
For the CAR-T cell product, therapeutic effects were reported in 5 patients in a clinical study at Chulalongkorn University in Thailand. Nagoya University indicated plans to initiate a physician-initiated clinical trial in Japan for malignant lymphoma and the company's plans to manufacture the CAR-T cells for the trial. - FY2023-Q3AdvancedAnnual report
「In addition, the company will apply the knowledge and expertise gained through development of this product to full-scale business expansion in the oncology field by collaborating with TEIJIN LIMITED, the National Cancer Center, and Mitsui Fudosan Co.,Ltd. through the "regenerative medicine platform" being established in Kashiwanoha Smart City.」
The company has newly outlined its policy of applying the knowledge and expertise gained through development of the autologous CAR-T cell product to collaboration on the regenerative medicine platform in Kashiwanoha and business expansion in the oncology field. - FY2023-Q2RestatedAnnual report
「Since 2019, the company has advanced development of an autologous CAR-T cell product intended to treat CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia) under a 3-year AMED grant program for research and development toward initiating a company-sponsored clinical trial of an autologous CD19 CAR-T therapy using a piggyBac transposon vector, namely, development of a domestically produced CAR-T cell product using a new technology that does not use viral vectors.」
For the autologous CAR-T cell product using a non-viral vector, the company continues to aim to initiate a company-sponsored clinical trial based on the AMED grant program and Nagoya University's clinical study. - FY2023-Q1RestatedAnnual report
「Since 2019, the company has advanced development of an autologous CAR-T cell product intended to treat CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia) under a 3-year AMED grant program for research and development toward initiating a company-sponsored clinical trial of an autologous CD19 CAR-T therapy using a piggyBac transposon vector, namely, development of a domestically produced CAR-T cell product using a new technology that does not use viral vectors. In parallel, Nagoya University, the source of the technology license, is conducting a clinical study using the technology for acute lymphoblastic leukemia, accumulating evaluation data toward a company-sponsored clinical trial. The company aims to initiate the company-sponsored clinical trial in the future.」
For the autologous CAR-T cell product using a non-viral vector, the company continues to aim to initiate a company-sponsored clinical trial based on the AMED grant program and Nagoya University's clinical study. - FY2022-Q1AdvancedAnnual report
「In parallel, Nagoya University, the source of the technology license, is conducting a clinical study using the technology for acute lymphoblastic leukemia. Dosing of 3 patients in the first cohort, covering ages 16 to 60, has been completed, and safety and a certain degree of efficacy have been confirmed.」
For the autologous CAR-T cell therapy, dosing of 3 patients in the first cohort of Nagoya University's clinical study was completed, and safety and a certain degree of efficacy were confirmed. The accumulation of evaluation data toward a company-sponsored clinical trial progressed to a concrete stage. - FY2021-Q2RestatedAnnual report
「For autologous CAR-T cells intended to treat CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia), the company received an AMED grant in September 2019 for research and development toward initiating a company-sponsored clinical trial of an autologous CD19 CAR-T therapy using a piggyBac transposon vector, namely, development of a domestically produced CAR-T cell product using a new technology that does not use viral vectors, and is advancing development. In parallel, Nagoya University, the source of the technology license, is conducting a clinical study using the technology for acute lymphoblastic leukemia, accumulating evaluation data for a company-sponsored clinical trial.」
The company continues development of an autologous CAR-T cell therapy using a non-viral vector, supported by an AMED grant, as well as the clinical study at Nagoya University and accumulation of evaluation data for a company-sponsored clinical trial. - FY2021-Q1AdvancedAnnual report
「For autologous CAR-T cells intended to treat CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia), the company received an AMED grant in September 2019 for research and development toward initiating a company-sponsored clinical trial of an autologous CD19 CAR-T therapy using a piggyBac transposon vector, namely, development of a domestically produced CAR-T cell product using a new technology that does not use viral vectors, and is advancing development. In parallel, Nagoya University, the source of the technology license, is conducting a clinical study using the technology for acute lymphoblastic leukemia, accumulating evaluation data for a company-sponsored clinical trial.」
For the autologous CAR-T cell therapy, the clinical study at Nagoya University progressed, reaching the stage of accumulating evaluation data toward a company-sponsored clinical trial. - FY2020RestatedAnnual report
「For autologous CAR-T cells intended to treat CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia), the company received an AMED grant in September 2019 for research and development toward initiating a company-sponsored clinical trial of an autologous CD19 CAR-T therapy using a piggyBac transposon vector, and advanced development.」
The company continues research and development toward initiating a company-sponsored clinical trial of an autologous CAR-T cell therapy using a non-viral vector, supported by an AMED grant. - FY2020-Q3RestatedAnnual report
「In the development of an autologous CAR-T cell therapy for CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia), the company received an AMED grant in September 2019 for research and development toward initiating a company-sponsored clinical trial of an autologous CD19 CAR-T therapy using a piggyBac transposon vector, namely, development of a domestically produced CAR-T cell product using a new technology that does not use viral vectors, and continues to advance development.」
The company continues research and development toward initiating a company-sponsored clinical trial of an autologous CAR-T cell therapy using a non-viral vector, supported by an AMED grant. - FY2020-Q2AdvancedAnnual report
「In the development of an autologous CAR-T cell therapy for CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia), the company received a grant from the Japan Agency for Medical Research and Development (AMED) in September 2019 for research and development toward initiating a company-sponsored clinical trial of an autologous CD19 CAR-T therapy using a piggyBac transposon vector, namely, development of a domestically produced CAR-T cell product using a new technology that does not use viral vectors, and is advancing development.」
For the autologous CAR-T cell therapy, research and development toward initiating a company-sponsored clinical trial using non-viral piggyBac transposon vector technology progressed to the stage of obtaining an AMED grant. - FY2019-Q3RestatedAnnual report
「The company entered into a license agreement with Nagoya University and Shinshu University in June 2018 for the development of an autologous CAR-T cell therapy for CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia, ALL). The company is advancing development of the therapy in close collaboration with Nagoya University.」
The company continues to develop an autologous CAR-T cell therapy under its license agreement with Nagoya University and Shinshu University and in collaboration with Nagoya University. - FY2019-Q2RestatedAnnual report
「In June 2018, the company entered into license agreements with Nagoya University and Shinshu University for the development of an autologous CAR-T cell therapy for CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia, ALL). The company continues to collaborate with Nagoya University to bring this therapy into practical use at an early stage.」
The company continues its policy of bringing the CAR-T therapy into practical use at an early stage through the license agreements with Nagoya University and Shinshu University and collaboration with Nagoya University. - FY2019-Q1AdvancedAnnual report
「In June 2018, the company entered into an exclusive license agreement in Japan with Nagoya University and Shinshu University for patents covering low-cost manufacturing technology for autologous genetically modified T cells (CAR-T cells) targeting CD19-positive acute lymphoblastic leukemia (Acute Lymphoblastic Leukemia, ALL). Because the technology uses a vector based on a naturally derived enzyme rather than the conventional viral vector to introduce the CAR gene, it is expected to reduce manufacturing costs by eliminating the need for virus containment facilities and equipment, as well as quality testing for vector-derived viruses. The company is collaborating with Nagoya University to bring this therapy into practical use at an early stage.」
The company reiterated its disclosure of the exclusive license agreement with Nagoya University and Shinshu University and provided more detail on development aimed at early commercialization of a CAR-T therapy using low-cost, non-viral-vector manufacturing technology. - FY2018First statedAnnual report
「By combining the company's development and manufacturing expertise in regenerative medicine products with innovative technologies from Nagoya University and Shinshu University, the company aims to bring CAR-T therapy, a highly effective immune cell therapy, into practical use at an early stage.」
On 22 June 2018, the company entered into an exclusive patent license agreement in Japan with Nagoya University and Shinshu University concerning the development, use, manufacture and sale of an autologous CAR-T cell product for CD19-positive acute lymphoblastic leukemia.